SARS-CoV-2感染或COVID-19疫苗接种相关的皮肌炎
该回顾性研究纳入2020年3月1日至2022年10月31日在本院风湿科治疗的98例皮肌炎患者,其中12例(12.2%)在SARS-CoV-2感染或COVID-19疫苗接种后出现新发或复发症状。感染后症状平均出现时间为3.2天(中位0.5天),疫苗接种后平均5.75天(中位3.5天)。作者认为需进一步研究以理解该关联背后的可能病理生理机制。
要点
- 98例皮肌炎患者中12例(12.2%)在感染或疫苗接种后出现症状。
- 7例(58.3%)感染后出现症状,8例(66.7%)疫苗接种后出现症状。
- 9例(75%)肌炎特异性抗体阳性,3例(25%)肌炎相关抗体阳性。
核心结论
- 该回顾性综述显示,在大流行期间本院门诊评估的所有皮肌炎患者中,12.2%的患者其皮肌炎症状与COVID-19感染或疫苗接种存在强烈的时间关联。
- 需要进一步研究以理解该关联背后可能的病理生理机制。
研究设计与样本
- 回顾性综述,纳入2020年3月1日至2022年10月31日在本院风湿科接受治疗的皮肌炎患者,共98例。
- 查阅病历评估SARS-CoV-2感染或COVID-19疫苗接种后新发皮肌炎或原有皮肌炎复发的情况,并收集症状出现时间、疫苗接种时间、疫苗类型及疾病特征等数据。
主要发现
- 98例患者中12例(12.2%)在感染或疫苗接种后出现皮肌炎症状(新发或复发)。
- 12例中7例(58.3%)在感染后出现症状,8例(66.7%)在疫苗接种后出现症状,其中3例在感染和疫苗接种后均出现症状。
- COVID-19感染后症状平均出现时间为3.2天(中位0.5天),COVID-19疫苗接种后平均出现时间为5.75天(中位3.5天)。
- 12例中9例(75%)肌炎特异性抗体阳性,其余3例(25%)肌炎相关抗体阳性。
- 未发现与疫苗接种后皮肌炎症状出现相关的优势疫苗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: New-onset and relapsed dermatomyositis (DM) has been reported following SARS-CoV-2 infection or COVID-19 vaccination. This study aims to show the characteristics of a DM cohort after COVID-19 infection and vaccination. METHODS: A retrospective review was performed on patients treated for DM between March 1, 2020, and October 31, 2022. Charts were evaluated for the presence of new-onset DM or relapse of preexisting DM following either SARS-CoV-2 infection or COVID-19 vaccination. Data on symptom onset, timing of vaccination, type of vaccination, and disease characteristics were collected. RESULTS: Ninety-eight patients treated for DM at our institution in the Division of Rheumatology were included. In total, 12 of 98 patients (12.2%) experienced DM symptoms (either incident or relapse) following either infection or vaccination. Of the 12 patients who developed incident disease or relapse, 7 (58.3%) developed postinfection symptoms, and 8 (66.7%) developed symptoms after vaccination (3 patients had symptoms following both infection and vaccination). The mean onset of symptoms following COVID-19 infection was 3.2 days (median 0.5 days), and mean onset following COVID-19 vaccination was 5.75 days (median 3.5 days). Nine of 12 patients (75%) had a positive myositis-specific antibody, and the remaining 3 (25%) had myositis-associated antibodies. There was no predominant vaccine associated with the development of postvaccination DM symptoms. CONCLUSION: This retrospective review revealed a strong temporal relationship between DM symptoms and COVID-19 infection or vaccination in 12.2% of all patients with DM evaluated in our clinic during the pandemic. Additional studies are required to understand the possible pathophysiology behind this association.
引用
- Diaz-Menindez M, Sullivan MM, Wang B, et al. Dermatomyositis in Association With SARS-CoV-2 Infection or COVID-19 Vaccine. Arthritis Care Res (Hoboken). 2023. PMID: 37728071. doi:10.1002/acr.25236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。